GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Samsung BioLogics Co Ltd (XKRX:207940) » Definitions » Dividend-Payout-to-FFO

Samsung BioLogics Co (XKRX:207940) Dividend-Payout-to-FFO


View and export this data going back to 2016. Start your Free Trial

What is Samsung BioLogics Co Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Samsung BioLogics Co Business Description

Traded in Other Exchanges
N/A
Address
125, Cheomdan-daero, Yeonsu-gu, Incheon, KOR
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.